Purpose There is an urgent need for the development of a predictor of response to
chemotherapy for ER-positive breast cancer which is less chemosensitive than for ER-
negative breast cancer in order to avoid unnecessary chemotherapy. In the present study,
intrinsic subtyping by PAM50 was evaluated for its ability to predict a response to
chemotherapy. Patients and Methods For this study, 124 patients with ER-positive breast
cancer treated with neoadjuvant sequential paclitaxel and FEC (NAC) were evaluated …

CiNii 博士論文 - PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive
breast cancer … PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive
breast cancer ER陽性乳癌を対象としたPAM50分類による化学療法感受性の予測 … ER陽性
乳癌を対象としたPAM50分類による化学療法感受性の予測 …